STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 142683

TO:	From:
Deborah Lambkin **Location:** **Art Unit: 1626** **January 15, 2005** **Case Serial Number: 10/603054**	**P. Sheppard** **Location: Remsen Building** **Phone: (571) 272-2529** **sheppard@uspto.gov**

Search Notes

Access DB# 142683

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Deborah Lambkin Examiner #: 71300 Date: 1/12/05
Art Unit: 1626 Phone Number 30 2-0698 Serial Number: 10/603,059
Mail Box and Bldg/Room Location: Rm 5B07 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: A2A - Peptide agonists

Inventors (please provide full names): James Powers et al

Earliest Priority Filing Date: _____

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**



see Cl. 1 attached.

see also examples 1-14 attached

****

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: 1/13/05
Searcher Prep & Review Time: _____
Clerical Prep Time: _____
Online Time: _____

Type of Search

NA Sequence (#)_____
AA Sequence (#)_____
Structure (#) _____
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN _____
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis_____
Sequence Systems _____
WWW/Internet _____
Other (specify)_____

PTO-1590 (8-01)

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:38:33 ON 15 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Jan 2005  VOL 142 ISS 4
FILE LAST UPDATED: 14 Jan 2005  (20050114/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que
L1               STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   7

STEREO ATTRIBUTES: NONE
L3          245 SEA FILE=REGISTRY SSS FUL L1
L4           21 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3


=>
=>

=> d ibib abs hitrn l4 1-21

L4   ANSWER 1 OF 21  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        2004:102822  HCAPLUS
DOCUMENT NUMBER:         140:304069
TITLE:                   Design, Synthesis, and Evaluation of Aza-Peptide
                         Epoxides as Selective and Potent Inhibitors of
```

Caspases-1, -3, -6, and -8

AUTHOR(S): James, Karen Ellis; Asgian, Juliana L.; Li, Zhao Zhao; Ekici, Oeżlem Dogan; Rubin, John R.; Mikolajczyk, Jowita; Salvesen, Guy S.; Powers, James C.

CORPORATE SOURCE: School of Chemistry and Biochemistry, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332-0400, USA

SOURCE: Journal of Medicinal Chemistry (2004), 47(6), 1553-1574
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Aza-peptide epoxides, a novel class of irreversible protease inhibitors, are specific for the clan CD cysteine proteases. Aza-peptide epoxides with an aza-Asp residue at P1 are excellent irreversible inhibitors of caspases-1, -3, -6, and -8 with second-order inhibition rates up to 1 910 000 M-1 s-1. In general, the order of reactivity of aza-peptide epoxides is S,S > R,R > trans > cis. Interestingly, some of the R,R epoxides while being less potent are actually more selective than the S,S epoxides. Here, the aza-peptide epoxides designed for caspases are stable, potent, and specific inhibitors, as they show little to no inhibition of other proteases such as the aspartyl proteases porcine pepsin, human cathepsin D, plasmepsin 2 (from P. falciparum), HIV-1 protease, and the secreted aspartic proteinase 2 (SAP-2) from Candida albicans, the serine proteases granzyme B and α-chymotrypsin, and the cysteine proteases cathepsin B and papain (clan CA), and legumain (clan CD).

IT **646532-53-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases)

IT **477923-51-6P 477923-55-0P 646531-28-4P**
646531-29-5P 646531-50-2P 646531-60-4P
646531-61-5P 646531-62-6P 646531-63-7P
646531-64-8P 646531-65-9P 646531-66-0P
646531-67-1P 646531-68-2P 646531-69-3P
646531-70-6P 646531-71-7P 646531-72-8P
646531-73-9P 646531-74-0P 646531-75-1P
646531-77-3P 646531-78-4P 646531-79-5P
646531-80-8P 646531-81-9P 646531-82-0P
646531-83-1P 646531-84-2P 646531-85-3P
646531-86-4P 646531-87-5P 646531-88-6P
646531-89-7P 646531-90-0P 646532-38-9P
646532-39-0P 646532-40-3P 646532-41-4P
646532-54-9P 646532-55-0P 646532-56-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases)

IT **646531-03-5P 646531-04-6P 646531-05-7P**
646531-06-8P 646531-07-9P 646531-92-2P
646532-00-5P 646532-01-6P 646532-02-7P
646532-03-8P 646532-04-9P 646532-05-0P
646532-06-1P 646532-07-2P 646532-08-3P
646532-09-4P 646532-10-7P 646532-11-8P
646532-12-9P 646532-13-0P 646532-14-1P
646532-15-2P 646532-16-3P 646532-17-4P
646532-18-5P 646532-20-9P 646532-21-0P
646532-22-1P 646532-23-2P 646532-24-3P
646532-25-4P 646532-26-5P 646532-27-6P

646532-28-7P 646532-29-8P 646532-30-1P
646532-31-2P 646532-32-3P 646532-33-4P
646532-34-5P 646532-35-6P 646532-36-7P
646532-37-8P 676644-72-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases)

IT **646531-76-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases)

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:41455 HCAPLUS
DOCUMENT NUMBER: 140:111688
TITLE: Preparation of aza-peptide epoxides as protease inhibitors
INVENTOR(S): Powers, James C.; Asgian, Juliana L.; James, Karen E.; Li, Zhao-Zhao
PATENT ASSIGNEE(S): Georgia Tech Research Corporation, USA
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004005270	A1	20040115	WO 2003-US20290		20030626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2004048327	A1	20040311	US 2003-603054		20030624
PRIORITY APPLN. INFO.:			US 2002-394023P	P	20020705
			US 2002-394024P	P	20020705
			US 2002-394221P	P	20020705
			US 2003-603054	A	20030624

OTHER SOURCE(S): MARPAT 140:111688
GI



I

AB The invention discloses aza-peptide epoxides I [R1 is M1, M2-AA1, M2-AA2-AA1, or M2-AA3-AA2-AA1, where M1 is NH2CO, NH2CS, NH2SO2, etc.; M2 is H, NH2CO, NH2CS, NH2SO2, etc.; AA1, AA2, and AA3 are side chain-blocked or unblocked amino acids with the L- or D-configuration or no chirality; R2 is (un)substituted alkyl, Ph, or naphthyl; R3 is (un)substituted (cyclo)alkyl, CO2H or esters, carboxamido groups, including amino acid derivs.] and their pharmaceutically-acceptable salts that inhibit protease, e.g., cysteine proteases, and can be used to treat viral infections, stroke, neurodegenerative disease, inflammatory disease, etc. Thus, trans-3-[N2-[N-(tert-butoxycarbonyl)norvalyl]-N1-phenethylhydrazinocarbonyl]-2-oxiranecarboxylic acid Et ester was prepared by amidation of Et trans-epoxysuccinate with Boc-Nva-NHNHCH2CH2Ph and showed inhibition constant kobs/[I] (M-1s-1) = 1.4 and 2.7 for inhibition of papain and cathepsin B, resp.

IT **646531-21-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aza-peptide epoxides as protease inhibitors)

IT **477923-51-6P 477923-55-0P 477923-59-4P**
477923-63-0P 477923-67-4P 477923-71-0P
478038-74-3P 478038-75-4P 646531-03-5P
646531-04-6P 646531-05-7P 646531-06-8P
646531-07-9P 646531-08-0P 646531-09-1P
646531-10-4P 646531-11-5P 646531-12-6P
646531-13-7P 646531-14-8P 646531-15-9P
646531-16-0P 646531-17-1P 646531-18-2P
646531-19-3P 646531-22-8P 646531-23-9P
646531-24-0P 646531-25-1P 646531-26-2P
646531-27-3P 646531-28-4P 646531-29-5P
646531-30-8P 646531-31-9P 646531-32-0P
646531-33-1P 646531-34-2P 646531-36-4P
646531-38-6P 646531-40-0P 646531-41-1P
646531-42-2P 646531-43-3P 646531-44-4P
646531-45-5P 646531-46-6P 646531-47-7P
646531-48-8P 646531-49-9P 646531-50-2P
646531-51-3P 646531-52-4P 646531-53-5P
646531-54-6P 646531-55-7P 646531-56-8P
646531-57-9P 646531-58-0P 646531-59-1P
646531-60-4P 646531-61-5P 646531-62-6P
646531-63-7P 646531-64-8P 646531-65-9P
646531-66-0P 646531-67-1P 646531-68-2P
646531-69-3P 646531-70-6P 646531-71-7P
646531-72-8P 646531-73-9P 646531-74-0P
646531-75-1P 646531-76-2P 646531-77-3P
646531-78-4P 646531-79-5P 646531-80-8P
646531-81-9P 646531-82-0P 646531-83-1P
646531-84-2P 646531-85-3P 646531-86-4P
646531-87-5P 646531-88-6P 646531-89-7P
646531-90-0P 646531-91-1P 646531-92-2P
646531-93-3P 646531-94-4P 646531-95-5P
646531-96-6P 646531-97-7P 646531-98-8P
646531-99-9P 646532-00-5P 646532-01-6P
646532-02-7P 646532-03-8P 646532-04-9P
646532-05-0P 646532-06-1P 646532-07-2P
646532-08-3P 646532-09-4P 646532-10-7P
646532-11-8P 646532-12-9P 646532-13-0P
646532-14-1P 646532-15-2P 646532-16-3P
646532-17-4P 646532-18-5P 646532-20-9P
646532-21-0P 646532-22-1P 646532-23-2P

646532-24-3P 646532-25-4P 646532-26-5P
646532-27-6P 646532-28-7P 646532-29-8P
646532-30-1P 646532-31-2P 646532-32-3P
646532-33-4P 646532-34-5P 646532-35-6P
646532-36-7P 646532-37-8P 646532-38-9P
646532-39-0P 646532-40-3P 646532-41-4P
646532-42-5P 646532-43-6P 646532-44-7P
646532-45-8P 646532-46-9P 646532-47-0P
646532-48-1P 646532-49-2P 646532-50-5P
646532-52-7P 646532-53-8P 646532-54-9P
646532-55-0P 646532-56-1P 646532-57-2P
646532-58-3P 646532-59-4P 646532-60-7P
646532-61-8P 646532-62-9P 646532-63-0P
646532-64-1P 646532-65-2P 646532-66-3P
646532-67-4P 646532-68-5P 646532-69-6P
646533-05-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aza-peptide epoxides as protease inhibitors)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:10077 HCAPLUS
DOCUMENT NUMBER: 140:316968
TITLE: Aza-peptide epoxides: potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases)
AUTHOR(S): James, Karèn Ellis; Goetz, Marion G.; Caffrey, Conor R.; Hansell, Elizabeth; Carter, Wendy; Barrett, Alan J.; McKerrow, James H.; Powers, James C.
CORPORATE SOURCE: School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332-0400, USA
SOURCE: Biological Chemistry (2003), 384(12), 1613-1618
CODEN: BICHF3; ISSN: 1431-6730
PUBLISHER: Walter de Gruyter GmbH & Co. KG
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Aza-peptide epoxides are a new class of irreversible cysteine protease inhibitors. Derivs. containing a P1 aza-asparagine residue are specific for Schistosoma mansoni and pig kidney legumains, which are clan CD cysteine proteases. The inhibitors have second-order rate consts. of up to 104 M-1S-1 with pig kidney legumain and IC50 values as low as 45 nM with S. mansoni legumain. The most potent epoxides contain an ester moiety with S,S stereochem. attached to the epoxide. Interestingly, amide and amino acid derivs. of the epoxysuccinate moiety were not inhibitors of legumain, while disubstituted amide derivs. are quite potent. The inhibitors have little or no inhibitory activity with other proteases such as caspases, chymotrypsin, papain, cathepsin B, granzyme B, and various aspartyl proteases.
IT **477923-59-4 477923-63-0 478038-74-3**
646531-18-2 646531-51-3 646531-52-4
646531-53-5 646531-54-6 646531-55-7
646531-56-8 646531-57-9 646531-58-0
646531-59-1
RL: PAC (Pharmacological activity); BIOL (Biological study)
(aza-peptide epoxides as potent and selective inhibitors of Schistosoma mansoni and pig kidney legumains (asparaginyl endopeptidases))
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:511091 HCAPLUS
DOCUMENT NUMBER: 139:85335
TITLE: Preparation of fused heterocyclic compounds and analogs thereof as modulators of nuclear hormone receptor function
INVENTOR(S): Salvati, Mark E.; Balog, James Aaron; Pickering, Dacia A.; Zhu, Hong
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053358	A2	20030703	WO 2002-US40737	20021218
WO 2003053358	A3	20031002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003181728	A1	20030925	US 2002-322276	20021218
EP 1467979	A2	20041020	EP 2002-798550	20021218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: US 2001-341962P P 20011219
WO 2002-US40737 W 20021218

OTHER SOURCE(S): MARPAT 139:85335
GI



I



II

AB Title compds. I [Z = O; n = 1-2; A1-2 = CR7; Y = J-J'-J''; J = alkyl; J' = bond, O, S, SO, etc.; J'' = alkyl; W = alkyl, alkenyl, etc.; Q1-2 = H, alkyl, alkenyl, cycloalkyl, etc; L = bond; G = aryl, heterocyclo] are prepared and methods of using such compds. in the treatment of nuclear hormone receptor-associated conditions. Thus, II is prepared by Diels-Alder reaction of cyclopentadiene with 2-(3-chloro-4-fluorophenyl)-1,1-dioxo-1,2-dihydroisothiazol-3-one (preparation given). As modulators of nuclear hormone receptor function, the use of I as potential anticancer agents and for treatment of immune disorders is claimed (no data).

IT **554412-98-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused thiazolone compds. and analogs thereof as modulators of nuclear hormone receptor function)

L4 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:789695 HCAPLUS
DOCUMENT NUMBER: 138:19120
TITLE: Aza-Peptide Epoxides: A New Class of Inhibitors Selective for Clan CD Cysteine Proteases
AUTHOR(S): Asgian, Juliana L.; James, Karen Ellis; Li, Zhao Zhao; Carter, Wendy; Barrett, Alan J.; Mikolajczyk, Jowita; Salvesen, Guy S.; Powers, James C.
CORPORATE SOURCE: School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332-0400, USA
SOURCE: Journal of Medicinal Chemistry (2002), 45(23), 4958-4960
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Aza-peptide epoxides, a new class of irreversible protease inhibitors, are specific for the clan CD cysteine proteases. The inhibitors have second-order rate consts. ≤105 M-1 s-1, with the most potent epoxides having the S,S stereochem. The aza-Asn derivs. are effective legumain inhibitors, while the aza-Asp epoxides were specific for caspases. The inhibitors have little or no inhibition with other proteases such as chymotrypsin, papain, or cathepsin B.

IT **477923-43-6 477923-47-0 477923-51-6 477923-55-0 477923-59-4 477923-63-0 477923-67-4 477923-71-0 478038-74-3 478038-75-4**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(aza-peptide epoxides as new class of inhibitors selective for clan CD cysteine proteases)

IT **477933-40-7 477933-41-8**
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(aza-peptide epoxides as new class of inhibitors selective for clan CD cysteine proteases)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:581860 HCAPLUS
DOCUMENT NUMBER: 135:152811
TITLE: Process for preparing 1,3,4-oxadiazole derivatives as intermediates for elastase inhibitors
INVENTOR(S): Sugiura, Tsuneyuki; Miyazaki, Toru; Horiuchi, Toshihide
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057005	A1	20010809	WO 2001-JP742	20010202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001030570	A5	20010814	AU 2001-30570	20010202
EP 1253143	A1	20021030	EP 2001-902738	20010202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: JP 2000-26718 A 20000203
WO 2001-JP742 W 20010202

OTHER SOURCE(S): CASREACT 135:152811; MARPAT 135:152811

GI



I

AB The title compds. I [R1 = Ph, etc.] are prepared by subjecting N3CH(CHMe2)CH(OH)CONHNHCOR1 [R1 = as given above] to the following reaction: protection of OH, cyclization, and deprotection for OH. I are then hydrogenated to the corresponding amine derivs. Thus, a mixture of N-(3-azido-2-hydroxy-4-methyl)pentanoyl-N'-(2,2-dimethylpropionyl)hydrazine, trimethylsilyl chloride, and pyridine in tert-Bu Me ether was stirred at room temperature for 30 min; the reaction mixture was then cooled, and thionyl chloride was added to the reaction mixture; the resulting mixture was stirred with cooling for 30 min; magnesium sulfate was added to the reaction mixture, and the mixture was stirred at room temperature for 30 min; the reaction mixture was filtered, and the filtrate was concentrated; the resulting residue was dissolved in toluene, and the solution was refluxed for 20 min. The reaction mixture was cooled to room temperature; methanol and potassium fluoride were added to said mixture; the resulting mixture was stirred for 30 min and concentrated; the residue was dissolved in tert-Bu Me ether; the resulting solution was worked up to give 1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-2-azidobutanol which was subjected to hydrogenation to give 1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-2-aminobutanol.

IT **353237-74-8P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparing oxadiazole derivs. as intermediates for elastase inhibitors)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:213878 HCAPLUS
DOCUMENT NUMBER: 133:17731
TITLE: Highly stereoselective synthesis and biological properties of nucleoside analogues bearing a spiro inserted oxirane ring
AUTHOR(S): Tronchet, Jean M. J.; Kovacs, Imre; Seman, Michel; Dilda, Pierre; De Clercq, Erik; Balzarini, Jan
CORPORATE SOURCE: Department of Organic Pharmaceutical Chemistry, University of Geneva, Sciences II, Geneva, CH-1211/4, Switz.
SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2000), 19(4), 775-794
CODEN: NNNAFY; ISSN: 1525-7770
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:17731
GI



I

AB Starting from 2',5'-di-O-TBDMS-3'-ketouridine or its thymine analog, both xylo and ribo epimers of a series of 3"-substituted 3'-spiro-nucleosides, e.g. I, have been obtained in good yields and with a total stereoselectivity. Most new compds. were moderately cytotoxic with in some cases slightly selective antiproliferative activities. None of these compds. was active against HIV, but some other antiviral activities against HSV-2, CMV, EBV, or VZV, in the micromolar range, were noted in specific cases.

IT **272780-84-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(highly stereoselective synthesis and biol. properties of nucleoside analogs bearing a spiro inserted oxirane ring)

IT **272780-85-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(highly stereoselective synthesis and biol. properties of nucleoside

analogs bearing a spiro inserted oxirane ring)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:550659 HCAPLUS
DOCUMENT NUMBER: 129:260379
TITLE: Synthesis of optically active 4-hydroxypyrazolidin-3-ones as precursors for β-amino α-hydroxy carboxylic acid derivatives
AUTHOR(S): Woydowski, Karsten; Liebscher, Juergen
CORPORATE SOURCE: Inst. Chem., Humboldt-Univ., Berlin, D-10115, Germany
SOURCE: Journal fuer Praktische Chemie/Chemiker-Zeitung (1998), 340(6), 567-571
CODEN: JPCCEM; ISSN: 0941-1216
PUBLISHER: Johann Ambrosius Barth
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:260379
AB Cis- and trans-glycidic esters give ring transformations with hydrazines to afford optically active 4-hydroxypyrazolidin-3-ones with different regioselectivities. Subsequent hydrogenation in the presence of Raney-Ni leads to enantiomerically pure β-amino α-hydroxy carboxamides.
IT **213621-79-5P 790662-80-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hydroxypyrazolidinones and reductive cleavage to β-amino α-hydroxy carboxamides)

L4 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:265567 HCAPLUS
DOCUMENT NUMBER: 125:33462
TITLE: Oxiranes with quinoline substitution: stereoselective synthesis and antiviral activity
AUTHOR(S): Kidwai, M.; Kumar, Kaushlendra; Goel, Yogesh; Srivastava, K. C.
CORPORATE SOURCE: Dep. Chem., Univ. Delhi, Delhi, 110 007, India
SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(7), 871-4
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of new quinoline substituted oxiranes were prepared from chloroacetic acid 2-(2-quinolinyl)hydrazide and aromatic aldehydes. The target compds. were I (R = Ph, pyridinyl, etc.). I were tested against encephalomyocarditis virus (EMCV) and only two compds. exhibited protection against the virus.

IT **177612-02-1P 177612-04-3P 177612-06-5P**
177612-07-6P 177612-09-8P 177612-10-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and virucidal activity of oxiranecarboxylic (quinolinyl)hydrazides)
IT **177612-03-2P 177612-05-4P 177612-08-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and virucidal activity of oxiranecarboxylic (quinolinyl)hydrazides)

L4 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:97020 HCAPLUS
DOCUMENT NUMBER: 124:232084
TITLE: Synthetic studies of novel 5-azacarbapenems
AUTHOR(S): Oda, Kuniyuki; Nakano, Takao; Morimoto, Hiroshi; Takamura, Norio
CORPORATE SOURCE: Org. Chem. Res. Lab., Tanabe Seiyaku Co., Ltd., Saitama, 335, Japan
SOURCE: Heterocycles (1996), 42(2), 577-88
CODEN: HTCYAM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 1,2-Diazetidinones were prepared from (2R,3R)-epoxybutanoic acid via acidic one-pot deprotection-cyclization reaction and converted to the novel 5-azacarbapenams by an intramol. Michael cyclization reaction.
IT **174787-19-0P 174787-20-3P 174787-21-4P**
174787-24-7P 174787-25-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diazetidinones and azacarbapenams)

L4 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:323366 HCAPLUS
DOCUMENT NUMBER: 120:323366
TITLE: ring transformations of 1-oxa-5,6-diazaspiro[2.4]hept-6-en-4-ones into 4,5-dihydro-4-hydroxy-1H-pyrazole-4-carboxylic acid derivatives
AUTHOR(S): Kirschke, Klaus; Huebner, Petra; Lutze, Gerhard; Gruendemann, Egon; Ramm, Matthias
CORPORATE SOURCE: Zent. Selektive Org. Synth., Berlin-Adlershof, D-12484, Germany
SOURCE: Liebigs Annalen der Chemie (1994), (2), 159-65
CODEN: LACHDL; ISSN: 0170-2041
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 120:323366
GI



I

II



III

AB Spiro epoxides I [R = Ph, 4-O2NC6H4; R1 = OEt, pyrrolidino, Me; R2 = Ph, R3 = H; R2 = R3 = Me] were synthesized from 1H-pyrazol-5(4H)-ones by Knoevenagel condensation with R2R3CO and subsequent epoxidn. with hydrogen peroxide. I react with nucleophiles to give 4,5-dihydro-4-hydroxy-1H-pyrazole-4-carboxylic acid derivs. II [R4 = NH2, OMe, OCHMeEt, NHNH2]. In three cases the intermediate ring-opened hydrazone was isolated. On dehydrogenation with chloranil II [R = 4-O2NC6H4, R1 = pyrrolidino, R2 = H, R3 = Ph, R4 = OMe, OCHMeEt] undergo rearrangement to 4,5-dihydro-4-oxo-1H-pyrazole-5-carboxylic acid derivs. III.

IT **154926-12-2P 154926-13-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

IT **154926-11-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L4 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:634333 HCAPLUS
DOCUMENT NUMBER: 117:234333
TITLE: Synthesis of 17α-hydroxy-20-oxopregnanes from 17(20)-dehydro-23,24-dinorcholan-22-oic acids
AUTHOR(S): Toro, Andras; Ambrus, Gabor
CORPORATE SOURCE: Inst. Drug Res., Budapest, H-1325, Hung.
SOURCE: Tetrahedron Letters (1992), 33(36), 5265-6
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:234333

AB Title transformation involving catalytic epoxidn., azidation, Curtius rearrangement and acidic hydrolysis has been accomplished. This synthetic sequence offers a novel route from a partial microbial side chain degradation product of natural sterols into useful precursors of antiinflammatory, antiandrogen and gestagen pharmaceuticals.

IT **144490-19-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acid hydrolysis of)

L4 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:235964 HCAPLUS
DOCUMENT NUMBER: 116:235964
TITLE: Process for producing 17α-hydroxy-20-oxopregnane steroid derivatives
INVENTOR(S): Toro, Andras; Ambrus, Gabor; Pallagi, Istvan; Makk, Nandor; Horvath, Gyula; Szederkenyi, Ferenc; Ilkoy, Eva; Jekkel, Antale, Mrs.; Moravcsik, Imre; Konczol, Kalman
PATENT ASSIGNEE(S): Gyogyszerkutato Intezet, Hung.
SOURCE: Hung. Teljes, 17 pp.
CODEN: HUXXBU
DOCUMENT TYPE: Patent
LANGUAGE: Hungarian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 58105	A2	19920128	HU 1990-3896	19900619
HU 208022	B	19930728		
CA 2044973	AA	19911220	CA 1991-2044973	19910619
EP 469275	A2	19920205	EP 1991-110026	19910619
EP 469275	A3	19920325		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CN 1058970	A	19920226	CN 1991-105033	19910619
CN 1030919	B	19960207		
US 5241063	A	19930831	US 1991-717823	19910619
SK 278135	B6	19960207	SK 1991-1880	19910619
JP 09118687	A2	19970506	JP 1991-173444	19910619

PRIORITY APPLN. INFO.: HU 1990-3896 A 19900619
OTHER SOURCE(S): CASREACT 116:235964
GI



I



II

AB Stereoselective epoxidn. of dehydrodinorcholanoic acids (e.g., I) with H2O2 in an N-containing organic solvent in the presence of catalytic ammonium paramolybdate or sodium tungstate afforded the 17α,20α epoxy acid derivative; conversion of the latter to acid azide, followed by warming in acidic alc. media, resulted in rearrangement to the corresponding hydroxyoxopregnane (e.g., II). Thus, to 10.22 g cholatrienoic acid I in 150 mL pyridine were added 10 mL 20% aqueous sodium tungstate and subsequently 10 mL 30% H2O2 at 60°; workup afforded 97% 17α,20α epoxide (III). To 5.36 g III and 2.1 mL Et3N in CH2Cl2 were added 1.95 mL iso-Bu chloroformate (anhydride formation), and subsequently 1.46 g NaN3 in 15 mL H2O; workup afforded 95% acid azide (IV). A solution consisting of 3.81 g IV in 150 mL EtOH and 100 mL 50% aqueous AcOH was maintained at boiling for 3 h; workup afforded 97% II.

IT **140700-46-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation and rearrangement of)

L4 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:6408 HCAPLUS
DOCUMENT NUMBER: 116:6408
TITLE: Preparation of aminoindolecarboxamide derivatives as neoplasm inhibitors
INVENTOR(S): Mongelli, Nicola; D'Alessio, Roberto; Grandi, Maria; Spreafico, Federico
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.r.l., Italy
SOURCE: Ger. Offen., 9 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4106860	A1	19910919	DE 1991-4106860	19910304
GB 2241950	A1	19910918	GB 1990-5529	19900312
GB 2241950	B2	19930512		
JP 05148227	A2	19930615	JP 1991-67875	19910307

PRIORITY APPLN. INFO.: GB 1990-5529 A 19900312
OTHER SOURCE(S): MARPAT 116:6408
GI



I

AB Title compds. [I; A = 14, NHCOR1, NR2R3; R1 = 2-haloacryloyl, (substituted) oxiranyl; R2, R3 = H, halo- or R4O2SO-substituted alkyl; R4 = alkyl, Ph; B = H, (CH2)mNHCOR1; m = 0-3; Z, Z1 = CH, CH:CH; X = N, O, S; n = 0, 1], were prepared Thus, a solution of H2C:CBrCO2H and Et3N in THF at -10° was treated with Me3CCOCl; Et3N.HCl was filtered off and the soln was added to a DMF solution of 5-(benzofuran-2-carboxamido)indol-2-carbohydrazide to give 2'-(α-bromoarcryloyl)-5-(benzofuran-2-carboxamido)indol-2-carbohydrazide (II). II had IC50 of 0.188 μg/mL against <1210 leukemia. An injection containing II was prepared
IT **137855-52-8P 137855-53-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as neoplasm inhibitor)

L4 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1991:206680 HCAPLUS
DOCUMENT NUMBER: 114:206680
TITLE: Antihypertensive hydrazidones: study of acylated 2-chlorobenzylidenehydrazines

AUTHOR(S): Galons, H.; Cave, C.; Miocque, M.; Rinjard, P.; Tran, G.; Binet, P.
CORPORATE SOURCE: Lab. Chim. Org., Fac. Pharm., Chatenay-Malabry, F 92290, Fr.
SOURCE: European Journal of Medicinal Chemistry (1990), 25(9), 785-8
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 114:206680
GI



I

AB Fifty-five hydrazones I (R = H, Me, Et, Bu, CH2OH; R1 = CMe2OH, 3,4,5-trimethoxyphenyl, CONH2, 3-pyridyl, etc.) were prepared from the carbonyl compds. and the acylhydrazines. Antihypertensive min. dosage for I in rats are tabulated.

IT **5814-13-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with carbonyl compound)

IT **133662-11-0P 133662-12-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antihypertensive activity of)

L4 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1984:406947 HCAPLUS
DOCUMENT NUMBER: 101:6947
TITLE: Synthesis of α,β-epoxyacyl azides and their rearrangement to epoxy isocyanates and 3- and 4-oxazolin-2-ones
AUTHOR(S): Lemmens, Jacques M.; Blommerde, Willem W. J. M.; Thijs, Lambertus; Zwanenburg, Binne
CORPORATE SOURCE: Dep. Org. Chem., Univ. Nijmegen, Nijmegen, 6525 ED, Neth.
SOURCE: Journal of Organic Chemistry (1984), 49(12), 2231-5
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 101:6947
GI



I, R=CO_2Et
II, R=CON_3
III, R=CO_2COCMe_3
IV, R=COCl
VI, R=isocyanato



V



VII



VIII



IX

AB The conversion of α,β-epoxy carboxylates I [R1 = Ph, 4-O2NC6H4, 4-MeC6H4, Me; R2 = H, Ph, Me; R3 = H, Ph, Me, 4-MeC6H4, 4-MeOC6H4; R1R3 = (CH2)5, R2 = H; R1CR2 = adamantane moiety, R3 = H; R1R2 = (CH2)5, (CH2)4, R3 = Me, H] into α,β-epoxyacyl azides II proceeds either via reaction of the mixed anhydrides III with NaN3 or via reaction of epoxyacyl chlorides IV with HN3--pyridine. The latter method is preferred. The azides II undergo a smooth thermal Curtius rearrangement to give 4-oxazolin-2-ones V for the substrates II (R2 = H) having a H atom at Cβ. Monitoring this reaction by means of IR shows that the epoxy isocyanates VI are intermediates. Intramol. ring expansion of VI then leads to 3-oxazolin-2-ones VII that tautomerize to the 4-isomers V. Epoxyacyl azides II, having no H atom at Cβ, produce 3-oxazolin-2-ones VII as a proton shift is not possible. The products VII [R1CR2 = adamantane moiety, R3 = H; R1R2 = (CH2)5, R3 = Me] rapidly add water at the imine bond to give oxazolidin-2-ones VIII. Epoxy isocyanate VI [R1R2 = (CH2)5, R3 = H] is reasonably stable in solution; reaction with MeOH affords urethane IX.

IT **89848-92-0P 89848-93-1P 89848-94-2P**
89848-95-3P 89848-96-4P 89848-97-5P
89848-98-6P 89848-99-7P 89849-00-3P
89849-02-5P 89849-05-8P 89849-06-9P
89849-07-0P 89849-08-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and thermal rearrangement of, isocyanate by)

IT **89849-01-4P 89849-03-6P 89849-04-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L4 ANSWER 17 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1975:140001 HCAPLUS
DOCUMENT NUMBER: 82:140001
TITLE: Reaction of hydrazines with cis- and trans-epoxy esters
AUTHOR(S): Sabate-Alduy, Catherine; Bastide, Jean; Bercot, Pierre; Lematre, Jean
CORPORATE SOURCE: Lab. Synth. Org., Centre Univ. Perpignan, Perpignan, Fr.
SOURCE: Bulletin de la Societe Chimique de France (1974), (9-10, Pt. 2), 1942-8
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French
GI For diagram(s), see printed CA Issue.

AB Reaction of the epoxides cis-I (R = H, NO2; R1 = OEt) and trans-I (R = H, NO2, OMe, Cl; R1 = OEt) with NH2NH2 gave the hydrazides I (R1 = NHNH2), which was cyclized to the pyrazolidinones II (R2 = H) in boiling EtOH. I and MeNHNH2 or PhNHNH2 gave II (R2 = Me, Ph) directly. The stereochem. of I was preserved in II. Kinetics and mechanism of the cyclization are discussed. Only II (R = H, R2 = Me, Ph) could be aromatized.

IT **54679-41-3P 54679-42-4P 54679-43-5P**
54679-44-6P 54679-45-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

L4 ANSWER 18 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1970:455891 HCAPLUS
DOCUMENT NUMBER: 73:55891
TITLE: Synthesis of some glycidic hydrazides and amides as potential psychotropic agents and anticholinergic agents
AUTHOR(S): Saenz, Reynaldo V.; Brown, Robert Graves; Isaacson, Eugene I.; Delgado, Jaime N.
CORPORATE SOURCE: Coll. of Pharm., Univ. of Texas, Austin, TX, USA
SOURCE: Journal of Pharmaceutical Sciences (1970), 59(7), 942-7
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB A series of glycidic hydrazides, e.g. I, and amides was prepared by hydrazinolysis or aminolysis of glycidic esters obtained via a modified Darzens condensation. The hydrazides were subjected to acylating or alkylating reagents to obtain N-substituted hydrazides. The results of preliminary pharmacol. evaluation are summarized. The compds. were tested for their ability to reverse reserpine hypothermia in mice. Compds. synthesized as potential anticholinergics were evaluated for their spasmolytic activity using isolated rabbit ileum.
IT **27244-07-1P 27244-19-5P 28922-85-2P**
28922-87-4P 28922-88-5P 28922-91-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L4 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1967:490589 HCAPLUS
DOCUMENT NUMBER: 67:90589
TITLE: 2,3-Epoxysuccinic anhydride
AUTHOR(S): Creighton, Stephen M.; Mitchell, David Lawrence
CORPORATE SOURCE: Res. Council Alberta, Edmonton, Can.
SOURCE: Canadian Journal of Chemistry (1967), 45(11), 1304-6
CODEN: CJCHAG; ISSN: 0008-4042
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Highly strained 2,3-epoxysuccinic anhydride (I) is prepared by dehydrating cis-2,3-epoxysuccinic acid (II) using ethereal dicyclohexylcarbodiimide (III). I could not be prepared by pyrolysis of II, treatment with Ac2O, or treatment with PhNCO. The anhydride functional group undergoes ring opening with aromatic amines and aromatic hydrazines to give 1:1 amide-hydrazide.
IT **16191-23-4P 16191-24-5P 16191-25-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L4 ANSWER 20 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1966:15753 HCAPLUS
DOCUMENT NUMBER: 64:15753
ORIGINAL REFERENCE NO.: 64:2869g-h
TITLE: Infrared spectra of carboxylic acid derivatives. IV. Amides and hydrazides
AUTHOR(S): Jart, A.
SOURCE: Acta Polytech. Scand., Chem. Met. Ser. (1965), No. 42, 55 pp.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB cf. CA 63, 14654f. The ir spectra of 91 carboxylic acid amides, 6 thioamides, and 11 sulfonamides, as well as 30 carboxylic acid monohydrazides, and 3 sym. dihydrazides are given. The spectra were recorded by means of a Perkin-Elmer grating spectrophotometer, model 421, within the range 550-4000 cm.-1 by using the KBr disk technique. Some of the amides and hydrazides prepared have not been described previously in the literature. M.ps. are given for all the compds. considered.
IT **5814-13-1**, Glycidic acid, 3-phenyl-, hydrazide (spectrum of)

L4 ANSWER 21 OF 21 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1963:462304 HCAPLUS
DOCUMENT NUMBER: 59:62304
ORIGINAL REFERENCE NO.: 59:11484d-g
TITLE: Derivatives of 1,2,3-trimethoxybenzene. II. Amides and hydrazides of trimethylgallic acid
AUTHOR(S): Schlager, L. H.
CORPORATE SOURCE: Arzneimittelfabrik W. Spitzner G.m.b.H., Ettlingen/Baden, Germany
SOURCE: Arch. Pharm. (1963), 296, 217-26
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. Arzneimittel-Forsch. 13(3), 226-34(1963). Derivs. of 3,4,5-(MeO)3C6H2CONRNR1R2 (I), containing groups known to be pharmacol. active, have been prepared by reactions of 3,4,5-(MeO)3C6H2COCl (II) or 3,4,5-(MeO)3C6H2-CONHNH2 (III). β-Morpholinopropionylhydrazine (8 g.) [m. 66-9°, quant. yield by dropping 300 g. Me β-morpholinopropionate into 95 g. NH2NH2.H2O in 200 ml. EtOH, stirring 1 hr. at 60°, evaporating, and crystallizing; salicylidenehydrazone m. 149-51°] in 50 ml. absolute dioxane dropped into 40 ml. absolute dioxane containing 10.5 g. II and the mixture stirred 2 hrs. at 50° yielded 62.5% 1-(3,4,5-trimethoxybenzoyl)-2-(β-morpholinopropionyl)hydrazine-HCl, m. 234.5-36° (decomposition) (EtOH-Et2O). β-Methyl-β-phenylglycidic acid hydrazide (8 g.) (m. 126-7°, 11.8% yield by stirring 91 g. the acid with 30 g. NH2NH2.H2O at room temperature) in 20 ml. absolute C5H5N dropped into a boiling solution of 9.4 g. II in 50 ml. absolute Et2O, the solution decanted from the oil, the oil in CHCl3 shaken with H2O, dried, treated with C and precipitated with CCl4 yielded 14.6% IIIa (R = H, R1 = β-methyl-β-phenylglycid-amido), m. 143.5-4.5° (CHCl3-Et2O). The following IIIa were similarly prepared (R, R1, m.p., % yield given): H, 2-methyl-4-oxo-3,4-dihydroquinazolin-3-yl, 220-2°, 75.6 (HCl salt m. 221-3°; H, IIIb, 224-5° (decomposition), 67.4; H, Me3CCONH (IV), 192-3°, 80.6 (a modification of IV, m. 218-18.5°, resulted by use of absolute dioxane as solvent and C5H5N in place of Et3N); H, NHCO2Et, 144-5°, 63.5; H, NHCONEt2, 183-4°, 67; H, (CH2)3OMe, 90.5-1.5°, 38.2; H, NHCSNH(CH2)2OMe, 169-70°, 87.3; H, 1-phenyl-2,3-dimethyl-5 oxopyrazolin-4-yl, 213-14° 71; (NRR1 =) 1-indazolyl, 105-5.5°, 81.4; (NRR1 =) 4,5,6,7-tetrahydroindazol-1-yl, 119.5-21.5°, 59.8; (NRR1 =) ethylenimino, 60-1°, 92.8; (NRR1 =)4-methylpiperazino,--(HCl salt m. 206.5-7.0°), 94.7; (NRR1 =) 2-phenyl-3-methylmorpholino, 111.5-12.5°, 70.3.

IT **90918-14-2**, Hydrocinnamic acid, α,β-epoxy-β-methyl-
, hydrazide **93331-74-9**, Hydrocinnamic acid, α,β-epoxy-
β-methyl-, salicylidenehydrazide **94680-73-6**, Hydrazine,
1-(α,β-epoxy-β-methylhydrocinnamoyl)-2-(3,4,5-
trimethoxybenzoyl)-
(preparation of)

=>
=>

=> fil reg
FILE 'REGISTRY' ENTERED AT 13:38:54 ON 15 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JAN 2005 HIGHEST RN 812631-13-3
DICTIONARY FILE UPDATES: 12 JAN 2005 HIGHEST RN 812631-13-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
=>

=> => d reg l3 tot

1	RN	790662-80-5	REGISTRY
2	RN	676644-72-7	REGISTRY
3	RN	646533-05-3	REGISTRY
4	RN	646532-69-6	REGISTRY
5	RN	646532-68-5	REGISTRY
6	RN	646532-67-4	REGISTRY
7	RN	646532-66-3	REGISTRY
8	RN	646532-65-2	REGISTRY
9	RN	646532-64-1	REGISTRY
10	RN	646532-63-0	REGISTRY
11	RN	646532-62-9	REGISTRY
12	RN	646532-61-8	REGISTRY
13	RN	646532-60-7	REGISTRY
14	RN	646532-59-4	REGISTRY
15	RN	646532-58-3	REGISTRY
16	RN	646532-57-2	REGISTRY
17	RN	646532-56-1	REGISTRY
18	RN	646532-55-0	REGISTRY
19	RN	646532-54-9	REGISTRY
20	RN	646532-53-8	REGISTRY
21	RN	646532-52-7	REGISTRY
22	RN	646532-51-6	REGISTRY
23	RN	646532-50-5	REGISTRY

24	RN	646532-49-2	REGISTRY
25	RN	646532-48-1	REGISTRY
26	RN	646532-47-0	REGISTRY
27	RN	646532-46-9	REGISTRY
28	RN	646532-45-8	REGISTRY
29	RN	646532-44-7	REGISTRY
30	RN	646532-43-6	REGISTRY
31	RN	646532-42-5	REGISTRY
32	RN	646532-41-4	REGISTRY
33	RN	646532-40-3	REGISTRY
34	RN	646532-39-0	REGISTRY
35	RN	646532-38-9	REGISTRY
36	RN	646532-37-8	REGISTRY
37	RN	646532-36-7	REGISTRY
38	RN	646532-35-6	REGISTRY
39	RN	646532-34-5	REGISTRY
40	RN	646532-33-4	REGISTRY
41	RN	646532-32-3	REGISTRY
42	RN	646532-31-2	REGISTRY
43	RN	646532-30-1	REGISTRY
44	RN	646532-29-8	REGISTRY
45	RN	646532-28-7	REGISTRY
46	RN	646532-27-6	REGISTRY
47	RN	646532-26-5	REGISTRY
48	RN	646532-25-4	REGISTRY
49	RN	646532-24-3	REGISTRY
50	RN	646532-23-2	REGISTRY
51	RN	646532-22-1	REGISTRY
52	RN	646532-21-0	REGISTRY
53	RN	646532-20-9	REGISTRY
54	RN	646532-18-5	REGISTRY
55	RN	646532-17-4	REGISTRY
56	RN	646532-16-3	REGISTRY
57	RN	646532-15-2	REGISTRY
58	RN	646532-14-1	REGISTRY
59	RN	646532-13-0	REGISTRY
60	RN	646532-12-9	REGISTRY
61	RN	646532-11-8	REGISTRY
62	RN	646532-10-7	REGISTRY
63	RN	646532-09-4	REGISTRY
64	RN	646532-08-3	REGISTRY
65	RN	646532-07-2	REGISTRY
66	RN	646532-06-1	REGISTRY
67	RN	646532-05-0	REGISTRY
68	RN	646532-04-9	REGISTRY
69	RN	646532-03-8	REGISTRY
70	RN	646532-02-7	REGISTRY
71	RN	646532-01-6	REGISTRY
72	RN	646532-00-5	REGISTRY
73	RN	646531-99-9	REGISTRY
74	RN	646531-98-8	REGISTRY
75	RN	646531-97-7	REGISTRY
76	RN	646531-96-6	REGISTRY
77	RN	646531-95-5	REGISTRY
78	RN	646531-94-4	REGISTRY
79	RN	646531-93-3	REGISTRY
80	RN	646531-92-2	REGISTRY
81	RN	646531-91-1	REGISTRY
82	RN	646531-90-0	REGISTRY
83	RN	646531-89-7	REGISTRY
84	RN	646531-88-6	REGISTRY
85	RN	646531-87-5	REGISTRY

86	RN	646531-86-4	REGISTRY
87	RN	646531-85-3	REGISTRY
88	RN	646531-84-2	REGISTRY
89	RN	646531-83-1	REGISTRY
90	RN	646531-82-0	REGISTRY
91	RN	646531-81-9	REGISTRY
92	RN	646531-80-8	REGISTRY
93	RN	646531-79-5	REGISTRY
94	RN	646531-78-4	REGISTRY
95	RN	646531-77-3	REGISTRY
96	RN	646531-76-2	REGISTRY
97	RN	646531-75-1	REGISTRY
98	RN	646531-74-0	REGISTRY
99	RN	646531-73-9	REGISTRY
100	RN	646531-72-8	REGISTRY
101	RN	646531-71-7	REGISTRY
102	RN	646531-70-6	REGISTRY
103	RN	646531-69-3	REGISTRY
104	RN	646531-68-2	REGISTRY
105	RN	646531-67-1	REGISTRY
106	RN	646531-66-0	REGISTRY
107	RN	646531-65-9	REGISTRY
108	RN	646531-64-8	REGISTRY
109	RN	646531-63-7	REGISTRY
110	RN	646531-62-6	REGISTRY
111	RN	646531-61-5	REGISTRY
112	RN	646531-60-4	REGISTRY
113	RN	646531-59-1	REGISTRY
114	RN	646531-58-0	REGISTRY
115	RN	646531-57-9	REGISTRY
116	RN	646531-56-8	REGISTRY
117	RN	646531-55-7	REGISTRY
118	RN	646531-54-6	REGISTRY
119	RN	646531-53-5	REGISTRY
120	RN	646531-52-4	REGISTRY
121	RN	646531-51-3	REGISTRY
122	RN	646531-50-2	REGISTRY
123	RN	646531-49-9	REGISTRY
124	RN	646531-48-8	REGISTRY
125	RN	646531-47-7	REGISTRY
126	RN	646531-46-6	REGISTRY
127	RN	646531-45-5	REGISTRY
128	RN	646531-44-4	REGISTRY
129	RN	646531-43-3	REGISTRY
130	RN	646531-42-2	REGISTRY
131	RN	646531-41-1	REGISTRY
132	RN	646531-40-0	REGISTRY
133	RN	646531-39-7	REGISTRY
134	RN	646531-38-6	REGISTRY
135	RN	646531-37-5	REGISTRY
136	RN	646531-36-4	REGISTRY
137	RN	646531-35-3	REGISTRY
138	RN	646531-34-2	REGISTRY
139	RN	646531-33-1	REGISTRY
140	RN	646531-32-0	REGISTRY
141	RN	646531-31-9	REGISTRY
142	RN	646531-30-8	REGISTRY
143	RN	646531-29-5	REGISTRY
144	RN	646531-28-4	REGISTRY
145	RN	646531-27-3	REGISTRY
146	RN	646531-26-2	REGISTRY
147	RN	646531-25-1	REGISTRY

148	RN	646531-24-0	REGISTRY
149	RN	646531-23-9	REGISTRY
150	RN	646531-22-8	REGISTRY
151	RN	646531-21-7	REGISTRY
152	RN	646531-20-6	REGISTRY
153	RN	646531-19-3	REGISTRY
154	RN	646531-18-2	REGISTRY
155	RN	646531-17-1	REGISTRY
156	RN	646531-16-0	REGISTRY
157	RN	646531-15-9	REGISTRY
158	RN	646531-14-8	REGISTRY
159	RN	646531-13-7	REGISTRY
160	RN	646531-12-6	REGISTRY
161	RN	646531-11-5	REGISTRY
162	RN	646531-10-4	REGISTRY
163	RN	646531-09-1	REGISTRY
164	RN	646531-08-0	REGISTRY
165	RN	646531-07-9	REGISTRY
166	RN	646531-06-8	REGISTRY
167	RN	646531-05-7	REGISTRY
168	RN	646531-04-6	REGISTRY
169	RN	646531-03-5	REGISTRY
170	RN	554412-98-5	REGISTRY
171	RN	478038-75-4	REGISTRY
172	RN	478038-74-3	REGISTRY
173	RN	477933-41-8	REGISTRY
174	RN	477933-40-7	REGISTRY
175	RN	477923-71-0	REGISTRY
176	RN	477923-67-4	REGISTRY
177	RN	477923-63-0	REGISTRY
178	RN	477923-59-4	REGISTRY
179	RN	477923-55-0	REGISTRY
180	RN	477923-51-6	REGISTRY
181	RN	477923-47-0	REGISTRY
182	RN	477923-43-6	REGISTRY
183	RN	353237-74-8	REGISTRY
184	RN	272780-85-5	REGISTRY
185	RN	272780-84-4	REGISTRY
186	RN	213621-79-5	REGISTRY
187	RN	177612-10-1	REGISTRY
188	RN	177612-09-8	REGISTRY
189	RN	177612-08-7	REGISTRY
190	RN	177612-07-6	REGISTRY
191	RN	177612-06-5	REGISTRY
192	RN	177612-05-4	REGISTRY
193	RN	177612-04-3	REGISTRY
194	RN	177612-03-2	REGISTRY
195	RN	177612-02-1	REGISTRY
196	RN	174787-25-8	REGISTRY
197	RN	174787-24-7	REGISTRY
198	RN	174787-21-4	REGISTRY
199	RN	174787-20-3	REGISTRY
200	RN	174787-19-0	REGISTRY
201	RN	154926-13-3	REGISTRY
202	RN	154926-12-2	REGISTRY
203	RN	154926-11-1	REGISTRY
204	RN	144490-19-7	REGISTRY
205	RN	140700-46-5	REGISTRY
206	RN	137855-53-9	REGISTRY
207	RN	137855-52-8	REGISTRY
208	RN	133662-12-1	REGISTRY
209	RN	133662-11-0	REGISTRY

```
210       RN              94680-73-6  REGISTRY
211       RN              93331-74-9  REGISTRY
212       RN              90918-14-2  REGISTRY
213       RN              89849-08-1  REGISTRY
214       RN              89849-07-0  REGISTRY
215       RN              89849-06-9  REGISTRY
216       RN              89849-05-8  REGISTRY
217       RN              89849-04-7  REGISTRY
218       RN              89849-03-6  REGISTRY
219       RN              89849-02-5  REGISTRY
220       RN              89849-01-4  REGISTRY
221       RN              89849-00-3  REGISTRY
222       RN              89848-99-7  REGISTRY
223       RN              89848-98-6  REGISTRY
224       RN              89848-97-5  REGISTRY
225       RN              89848-96-4  REGISTRY
226       RN              89848-95-3  REGISTRY
227       RN              89848-94-2  REGISTRY
228       RN              89848-93-1  REGISTRY
229       RN              89848-92-0  REGISTRY
230       RN              89303-92-4  REGISTRY
231       RN              54679-45-7  REGISTRY
232       RN              54679-44-6  REGISTRY
233       RN              54679-43-5  REGISTRY
234       RN              54679-42-4  REGISTRY
235       RN              54679-41-3  REGISTRY
236       RN              28922-91-0  REGISTRY
237       RN              28922-88-5  REGISTRY
238       RN              28922-87-4  REGISTRY
239       RN              28922-85-2  REGISTRY
240       RN              27244-19-5  REGISTRY
241       RN              27244-07-1  REGISTRY
242       RN              16191-25-6  REGISTRY
243       RN              16191-24-5  REGISTRY
244       RN              16191-23-4  REGISTRY
245       RN               5814-13-1  REGISTRY


=> d ide can 1 10 20 30 40 50 60 70 80 90 110 120 130 140 150 160170 180 190 200 210 220
230 240 245 l3
    245 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
ENTER ANSWER NUMBER OR RANGE (1):end

=> d ide can 1 10 20 30 40 50 60 70 80 90 110 120 130 140 150 160 170 180 190 200 210 220
230 240 245 l3

L3   ANSWER 1 OF 245  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   790662-80-5  REGISTRY
CN   Oxiranecarboxylic acid, 3-propyl-, hydrazide, (2R,3S)- (9CI)  (CA INDEX
     NAME)
FS   STEREOSEARCH
MF   C6 H12 N2 O2
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT
DT.CA  CAplus document type:  Journal
RL.NP  Roles from non-patents:  PREP (Preparation)

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:260379

L3 ANSWER 10 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646532-63-0 REGISTRY
CN L-Valine, N-[(phenylmethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-, 3-[2-(carboxymethyl)-2-[[3-[(2,3-dihydro-1H-indol-1-yl)carbonyl]oxiranyl]carbonyl]hydrazide] (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 163: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C36 H42 N6 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:111688

L3 ANSWER 20 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646532-53-8 REGISTRY
CN 2,3-Oxiranedicarboxylic acid, monoethyl ester, 1-(carboxymethyl)-2-[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]hydrazide, (2S,3S)-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 153: PN: WO2004005270 PAGE: 28-29 claimed sequence

FS STEREOSEARCH
MF C21 H27 N3 O9
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

L3 ANSWER 30 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646532-43-6 REGISTRY
CN L-Alanine, N-(1-oxo-3-phenylpropyl)-L-valyl-, 2-(carboxymethyl)-2-[[(2S,3S)-3-[[methyl(phenylmethyl)amino]carbonyl]oxiranyl]carbonyl]hydrazide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 144: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C31 H39 N5 O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:111688

L3 ANSWER 40 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646532-33-4 REGISTRY
CN L-Threonine, N-[(phenylmethoxy)carbonyl]-L-isoleucyl-L-α-glutamyl-, 2-(1,1-dimethylethyl) ester, 3-[2-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-[[(2S,3S)-3-[(phenylmethoxy)carbonyl]oxiranyl]carbonyl]hydrazide] (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 132: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C44 H61 N5 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

L3 ANSWER 50 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646532-23-2 REGISTRY
CN L-Valine, N-[(phenylmethoxy)carbonyl]-L-α-glutamyl-, 1-(1,1-dimethylethyl) ester, 2-[2-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-[[(2S,3S)-3-[[(2-phenylethyl)amino]carbonyl]oxiranyl]carbonyl]hydrazide] (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 122: PN: WO2004005270 PAGE: 28-29 claimed sequence

FS STEREOSEARCH
MF C40 H55 N5 O11
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

L3 ANSWER 60 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646532-12-9 REGISTRY
CN L-Alanine, N-(1-oxo-3-phenylpropyl)-L-valyl-, 2-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-[[(2S,3S)-3-[[[(1S)-1-methyl-2-oxo-2-[(phenylmethyl)amino]ethyl]amino]carbonyl]oxiranyl]carbonyl]hydrazide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 112: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C37 H50 N6 O9
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

L3 ANSWER 70 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646532-02-7 REGISTRY
CN L-Alanine, N-(1-oxo-3-phenylpropyl)-L-valyl-, 2-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-[[(2S,3S)-3-[(phenylmethoxy)carbonyl]oxiranyl]carbonyl]hydrazide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 102: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C34 H44 N4 O9
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

L3 ANSWER 80 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646531-92-2 REGISTRY
CN L-Threonine, N-[(phenylmethoxy)carbonyl]-L-leucyl-L-α-glutamyl-, 2-(1,1-dimethylethyl) ester, 3-[2-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-[[(2S,3S)-3-(ethoxycarbonyl)oxiranyl]carbonyl]hydrazide] (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 92: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C39 H59 N5 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

L3 ANSWER 90 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646531-82-0 REGISTRY
CN L-Valine, N-[(phenylmethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-, 3-[2-(carboxymethyl)-2-[[(2S,3S)-3-[[(2-phenylethyl)amino]carbonyl]oxiranyl]carbonyl]hydrazide] (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 82: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C36 H44 N6 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

L3 ANSWER 110 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646531-62-6 REGISTRY
CN L-Alanine, N-(1-oxo-3-phenylpropyl)-L-valyl-, 2-(carboxymethyl)-2-[[(2R,3R)-3-(ethoxycarbonyl)oxiranyl]carbonyl]hydrazide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 62: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C25 H34 N4 O9
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

L3 ANSWER 120 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646531-52-4 REGISTRY
CN L-Alanine, N-[(phenylmethoxy)carbonyl]-L-alanyl-, 2-(2-amino-2-oxoethyl)-2-(2,3-anhydro-4,5-dideoxy-5-phenylpentonoyl)hydrazide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 52: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C27 H33 N5 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:316968

REFERENCE 2: 140:111688

L3 ANSWER 130 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646531-42-2 REGISTRY
CN threo-Pentonic acid, 2,3-anhydro-4,5-dideoxy-5-phenyl-, 2-[(phenylmethoxy)carbonyl]-1-(phenylmethyl)hydrazide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 42: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C26 H26 N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:111688

L3 ANSWER 140 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646531-32-0 REGISTRY
CN L-Norvaline, N-[(1,1-dimethylethoxy)carbonyl]-, 2-(2,3-anhydro-4,5-dideoxy-5-phenylpentonoyl)-2-(2-phenylethyl)hydrazide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 35: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C29 H39 N3 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:111688

L3 ANSWER 150 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646531-22-8 REGISTRY
CN 2,3-Oxiranedicarboxylic acid, monoethyl ester, 2-[(2S)-2-[(3-carboxy-1-oxopropyl)amino]-3-(2-naphthalenyl)-1-oxopropyl]-1-(2-methylpropyl)hydrazide (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 25: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C27 H33 N3 O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:111688

L3 ANSWER 160 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 646531-12-6 REGISTRY
CN 2,3-Oxiranedicarboxylic acid, monoethyl ester, 2-[(2S)-4-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]pentyl]-1-(2-methylpropyl)hydrazide, (2R,3R)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 16: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C24 H35 N3 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:111688

L3 ANSWER 170 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 554412-98-5 REGISTRY
CN 3-Oxatricyclo[3.2.2.02,4]nonane-2-carboxylic acid, 1-[4-nitro-3-(trifluoromethyl)phenyl]hydrazide (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C16 H16 F3 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:85335

L3 ANSWER 180 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 477923-51-6 REGISTRY
CN L-Threonine, N-[(phenylmethoxy)carbonyl]-L-leucyl-L-α-glutamyl-, 3-[2-(carboxymethyl)-2-[[(2R,3R)-3-(ethoxycarbonyl)oxiranyl]carbonyl]hydrazide] (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 141: PN: WO2004005270 PAGE: 28-29 claimed sequence
FS STEREOSEARCH
MF C31 H43 N5 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:304069

REFERENCE 2: 140:111688

REFERENCE 3: 138:19120

L3 ANSWER 190 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 177612-07-6 REGISTRY
CN Oxiranecarboxylic acid, 3-(4-pyridinyl)-, 2-(4-methyl-2-quinolinyl)hydrazide, trans- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H16 N4 O2
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 125:33462

L3 ANSWER 200 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 174787-19-0 REGISTRY
CN Oxiranecarboxylic acid, 3-methyl-, (phenylmethylene)hydrazide, (2R-cis)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H12 N2 O2
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 124:232084

L3 ANSWER 210 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 94680-73-6 REGISTRY
CN Hydrazine, 1-(α,β-epoxy-β-methylhydrocinnamoyl)-2-(3,4,5-trimethoxybenzoyl)- (7CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H22 N2 O6
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: NORL (No role in record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 59:62304

L3 ANSWER 220 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 89849-01-4 REGISTRY
CN Oxiranecarbonyl azide, 3,3-diphenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H11 N3 O2
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 101:6947

L3 ANSWER 230 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 89303-92-4 REGISTRY
CN Succinic acid, epoxy-, dihydrazide (7CI) (CA INDEX NAME)
FS 3D CONCORD
MF C4 H8 N4 O3
LC STN Files: CAOLD



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L3 ANSWER 240 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 27244-19-5 REGISTRY
CN Oxiranecarboxylic acid, 3-(4-pyridinyl)-, 2-(3,4,5-trimethoxybenzoyl)hydrazide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydrazine, 1-[3-(4-pyridyl)glycidoyl]-2-(3,4,5-trimethoxybenzoyl)- (8CI)
FS 3D CONCORD
MF C18 H19 N3 O6
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 73:55891

L3 ANSWER 245 OF 245 REGISTRY COPYRIGHT 2005 ACS on STN
RN 5814-13-1 REGISTRY
CN Oxiranecarboxylic acid, 3-phenyl-, hydrazide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycidic acid, 3-phenyl-, hydrazide (7CI, 8CI)
FS 3D CONCORD
MF C9 H10 N2 O2
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: RACT (Reactant or reagent); NORL (No role in

record)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 114:206680

REFERENCE 2: 64:15753

=>